BAILEY FRISCH: Open Payments
NPI 1760046742 · SANTA ANA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,634 in 81 payments from 16 companies in 2025. Trend: 2023 $239 · 2024 $1,540 · 2025 $1,634
Food & beverage: $1,561Education: $74
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 9 | $332 |
| GENZYME CORPORATION | 9 | $236 |
| UCB, Inc. | 12 | $205 |
| Galderma Laboratories, L.P. | 13 | $151 |
| Janssen Biotech, Inc. | 8 | $151 |
| E.R. Squibb & Sons, L.L.C. | 4 | $87 |
| Novartis Pharmaceuticals Corporation | 4 | $80 |
| ABBVIE INC. | 4 | $75 |
| Organon LLC | 5 | $71 |
| Lilly USA, LLC | 3 | $64 |
Products named: DUPIXENT, Bimzelx, NEMLUVIO, TREMFYA, Sotyktu, SKYRIZI, COSENTYX, CIBINQO.
Industry payments across CA — which companies pay providers there.
